Gram-negative sepsis is a severe clinical syndrome associated with significant morbidity and mortality. Lipopolysaccharide (LPS), expressed on Gram-negative bacteria, is a potent pro-inflammatory toxin that induces inflammation and coagulation via two separate receptor systems. One is Toll-like receptor 4 (TLR4), expressed on cell surfaces and in endosomes, and the other is the cytosolic receptor caspase-11 (caspases-4 and -5 in humans). Extracellular LPS binds to high mobility group box 1 (HMGB1) protein, a cytokine-like molecule. The HMGB1-LPS complex is transported via receptor for advanced glycated end products (RAGE)-endocytosis to the endolysosomal system to reach the cytosolic LPS receptor caspase-11 to induce HMGB1 release, inflammation, and coagulation that may cause multi-organ failure. The insight that LPS needs HMGB1 assistance to generate severe inflammation has led to successful therapeutic results in preclinical Gram-negative sepsis studies targeting HMGB1. However, to date, no clinical studies have been performed based on this strategy. HMGB1 is also actively released by peripheral sensory nerves and this mechanism is fundamental for the initiation and propagation of inflammation during tissue injury. Homeostasis is achieved when other neurons actively restrict the inflammatory response via monitoring by the central nervous system and the vagus nerve through the cholinergic anti-inflammatory pathway. The neuronal control in Gram-negative sepsis needs further studies since a deeper understanding of the interplay between HMGB1 and acetylcholine may have beneficial therapeutic implications. Herein, we review the synergistic overlapping mechanisms of LPS and HMGB1 and discuss future treatment opportunities in Gram-negative sepsis.

Sepsis;Lipopolysaccharide (LPS);High mobility group box 1 (HMGB1);Toll-like receptor 4 (TLR4);Receptor for advanced glycated end products (RAGE);Caspase-11

Andersson Ulf;Yang Huan

Department of Women’s and Children’s Health, Karolinska Institute at Karolinska University Hospital, Stockholm 17176, Sweden;Institute for Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY 11030, United States of America

重症医学（英文）

[1]Andersson Ulf;Yang Huan-.HMGB1 is a critical molecule in the pathogenesis of Gram-negative sepsis ☆)[J].重症医学（英文）,2022(03):156-166

sepsis ,endolysosomal

HMGB1,critical,molecule,pathogenesis,Gram,negative,severe,syndrome,associated,significant,morbidity,mortality,Lipopolysaccharide,LPS,expressed,bacteria,potent,inflammatory,toxin,that,induces,inflammation,coagulation,via,two,separate,receptor,systems,One,Toll,like,TLR4,surfaces,endosomes,other,cytosolic,caspases,humans,Extracellular,binds,high,mobility,group,box,protein,cytokine,complex,transported,advanced,glycated,products,RAGE,endocytosis,reach,may,cause,multi,organ,failure,insight,needs,assistance,generate,has,led,successful,therapeutic,results,preclinical,studies,targeting,However,date,no,have,been,performed,this,strategy,also,actively,released,by,peripheral,sensory,nerves,fundamental,initiation,propagation,during,tissue,injury,Homeostasis,achieved,when,neurons,restrict,response,monitoring,central,nervous,vagus,through,cholinergic,anti,pathway,neuronal,control,further,since,deeper,understanding,interplay,between,acetylcholine,beneficial,implications,Herein,review,synergistic,overlapping,mechanisms,discuss,future,treatment,opportunities,Sepsis,High,Receptor,Caspase

0.540205